These FTSE 100 shares could rise 15% to 36% in the next year!

Is the market underestimating these top FTSE 100 stocks? Royston Wild explains why analysts expect these two blue-chip shares to rocket in value.

| More on:
Man smiling and working on laptop

Image source: Getty images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The UK’s FTSE 100 share index has gone gangbusters in recent months. It could have much further to run too, given the steady improvement in investor confidence and the enduring cheapness of British stocks.

These Footsie-listed companies look especially cheap at current prices. In fact, City analysts believe their shares will soar between 15% and 36% in value over the next 12 months.

Here’s what investors need to know about them.

GSK

A weak development pipeline means GSK (LSE:GSK) has underperformed the broader healthcare industry of late. But recent signs of recovery mean profits could be about to accelerate strongly.

Just last week, the firm reported positive Phase III results for its Depemokimab asthma battler. This follows four impressive outcomes at the same testing stage during the first quarter.

GSK now has almost 90 products in its R&D pipeline. Given its impressive track record of getting new products off the ground, it now looks in great shape to get sales firing again.

City brokers certainly think so. It’s why they predict earnings growth will speed up from 3% this year to 10% and 11% in 2025 and 2026 respectively.

Fifteen analysts currently have ratings on GSK shares. And the average 12-month price target among them stands at £20.32 per share. That’s a premium of around 15% from current levels.

Of course, success at the testing phase is never guaranteed. And any failures could erode GSK’s share price. But on balance, I think investing in the drugs developer could be a shrewd move.

JD Sports Fashion

While the wider FTSE 100 has soared, sportswear retailer JD Sports (LSE:JD.) has failed to join in on the recent rally. This reflects enduring fears over consumer spending, given higher-than-expected inflation in its markets and, in turn, the possibility of disappointing interest rate cuts.

However, the City believes that investors may be overly cautious at the moment. It expects JD’s share price to hit £168.80 apiece within the next 12 months. That represents a 36% increase from current levels, and is based on the average price forecasts from 15 analysts.

At the turn of 2024, JD cut its profit forecasts for the 12 months to January, and its share price has failed to recover since. But reassuring trading news since then suggests the FTSE firm may be over the worst.

In March, it said that trading was “in line with our expectations” during the first seven weeks of the new financial year.

It also predicted that “trading conditions will improve as we move through the year, helped by a busy sporting summer, softer comparatives with last year from Q2 and an improving product pipeline towards the end of the year“.

It’s early days in the new fiscal period, but City brokers certainly expect earnings to rise significantly from recent levels. Growth of 8% and 15% is predicted for fiscal 2025 and 2026 respectively, rebounding from the 12% decline recorded last year.

JD Sports has a brilliant record of growing ahead of the broader athleisure market. And as it continues expanding — it announced the planned acquisition of US sportswear chain Hibbett in April — I think both profits and its share price could surge from current levels.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black father holding daughter in a field of cows
Investing Articles

A FTSE 100 share that could create generational wealth

Investing in FTSE shares can help individuals pass down a significant chunk of cash to their children and grandchildren, data…

Read more »

Investing Articles

Here’s what the BT share price could mean for passive income investors

The BT share price has been falling for years, but that might be about to change. And dividends could be…

Read more »

Investing Articles

At £4.76, is the Aviva share price a steal? Here’s what the charts say!

Aviva has outperformed the Footsie over the last year. But is there still value in its share price? This Fool…

Read more »

Photo of a man going through financial problems
Investing Articles

Does a 43% price drop make this undervalued UK stalwart one of the best cheap shares to buy now?

After losing a third of its value of the past five years, this might be one of the most undervalued…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

My top 3 picks today for a £20,000 Stocks and Shares ISA

Here are three very different investments to consider for a Stocks and Shares ISA, covering both the UK and US…

Read more »

Businesswoman calculating finances in an office
Investing Articles

The Darktrace share price has been surging — and it could climb higher

I think the Darktrace share price could have more room to run. Despite the competitive AI industry, the firm looks…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

With its 7% dividend, should I be watching the Aviva share price?

Dividend investors will struggle to find many companies with a yield above 7%, so should the Aviva share price be…

Read more »

Investing Articles

Could this be one of the FTSE 100’s best cheap dividend shares?

Looking for the best dividend growth shares to buy? Our writer Royston Wild thinks this FTSE 100 housebuilder might well…

Read more »